{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"21.6"},{"groupId":"OG002","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Percentage of responders for each of the 10 NET indications considered in the study. Responder analyses were performed for an indication only if there were at least 6 patients in the efficacy analyzable set. For all other individual indications, the numbers of patients in the efficacy analyzable sets were less than 6 and therefore no responder analyses were carried out for these indications.","groups":[{"description":"One of the 10 types of PNETs analyzed","id":"OG000","title":"Gastrinoma"},{"description":"One of the 10 types of PNETs analyzed.","id":"OG001","title":"Prolactinoma"},{"description":"based on disease specific primary biochemical tumor markers. Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.","id":"OG002","title":"Nelson's Syndrome"}],"paramType":"NUMBER","populationDescription":"The efficacy analyzable set included all enrolled patients who received at least one dose of pasireotide LAR and had indication-specific baseline primary biochemical tumor marker levels \\>ULN.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Percentage of Responders at Month 6 - Individual NETs","type":"SECONDARY","unitOfMeasure":"percentage of participants"}